Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-07-2020 | osteosarcoma | Original Article – Cancer Research

Afatinib is active in osteosarcoma in osteosarcoma cell lines

Authors: Marlid Cruz-Ramos, Yessica Zamudio-Cuevas, Daniel Medina-Luna, Karina Martínez-Flores, Gabriela Martínez-Nava, Javier Fernández-Torres, Alberto López-Reyes, Flavio Solca

Published in: Journal of Cancer Research and Clinical Oncology | Issue 7/2020

Abstract

Purpose

Osteosarcoma is the most common bone tumor, mainly affecting adolescents and young adults, and metastatic disease has poor outcomes with a dismal overall survival. Currently, chemotherapy is the standard of care with limited results, finding that new therapies could improve these outcomes. Preclinical and clinical studies have suggested a possible important role of ErbB pathway aberrations in osteosarcoma etiology. The present study shows the effect of afatinib, an irreversible ErbB family blocker in osteosarcoma cell lines.

Methods

Within a panel of human osteosarcoma cell lines, we addressed cell viability assay using afatinib at increasing concentrations. Motility was measured in wound-healing assays and invasion capacity was assessed in Transwell chamber assays. Finally, to monitor ErbB pathway modulation by afatinib and related compounds, we used Western blot analyses.

Results

Cell viability inhibition, as well as a reduction of motility and migration of osteosarcoma cell line were observed after treatment with afatinib. Likewise, in the HOS cell line, afatinib decreased phosphorylation of key components in the ErbB signaling pathway.

Conclusions

Afatinib shows relevant antitumor effect in several osteosarcoma cell lines, as it causes a significant impact on cell viability, motility, and migration with a significant decrease in the activation of ErbB pathway activity.

Available only for authorised users

Allison DC, Carney SC, Ahlmann ER et al (2012) A meta-analysis of osteosarcoma outcomes in the modern medical era. Sarcoma. https://doi.org/10.1155/2012/704872CrossRefPubMedPubMedCentral

Bacci G, Briccoli A, Rocca M et al (2003) Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. Ann Oncol 14(7):1126–1134. https://doi.org/10.1093/annonc/mdg286CrossRefPubMed

Citri A, Yarden Y (2006) EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7(7):505–516. https://doi.org/10.1038/nrm1962CrossRefPubMed

Flick DA, Gifford GE (1984) Comparison of in vitro cell cytotoxic assays for tumor necrosis factor. J Immunol Methods 68(1–2):167–175. https://doi.org/10.1016/0022-1759(84)90147-9CrossRefPubMed

Gvozdenovic A, Boro A, Born W et al (2017) A bispecific antibody targeting IGF-IR and EGFR has tumor and metastasis suppressive activity in an orthotopic xenograft osteosarcoma mouse model. Am J Cancer Res 7(7):1435–1449PubMedPubMedCentral

Hughes DPM, Thomas DG, Giordano TJ et al (2004) Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. Cancer Res 64(6):2047–2053. https://doi.org/10.1158/0008-5472.can-03-3096CrossRefPubMed

Hughes DPM, Thomas DG, Giordano TJ et al (2006) Essential erbB family phosphorylation in osteosarcoma as a target for CI-1033 inhibition. Pediatr Blood Cancer 46(5):614–623. https://doi.org/10.1002/pbc.20454CrossRefPubMed

Jullien N, Dieudonné FX, Habel N et al (2013) ErbB3 silencing reduces osteosarcoma cell proliferation and tumor growth in vivo. Gene 521(1):55–61. https://doi.org/10.1016/j.gene.2013.03.031CrossRefPubMed

Kager L, Zoubek A, Pötschger U et al (2003) Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 21(10):2011–2018. https://doi.org/10.1200/JCO.2003.08.132CrossRefPubMed

Kansara M, Teng MW, Smyth MJ, Thomas DM (2014) Translational biology of osteosarcoma. Nat Rev Cancer 14(11):722–735. https://doi.org/10.1038/nrc3838CrossRefPubMed

Kersting C, Gebert C, Agelopoulos K et al (2007) Epidermal growth factor receptor expression in high-grade osteosarcomas is associated with a good clinical outcome. Clin Cancer Res 13(10):2998–3005. https://doi.org/10.1158/1078-0432.CCR-06-2432CrossRefPubMed

Kubo T, Piperdi S, Rosenblum J et al (2008) Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma. Cancer 112(10):2119–2129. https://doi.org/10.1002/cncr.23437CrossRefPubMed

Lee JA, Ko Y, Kim DH et al (2012) Epidermal growth factor receptor: Is it a feasible target for the treatment of Osteosarcoma? Cancer Res Treat 44(3):202–209. https://doi.org/10.4143/crt.2012.44.3.202CrossRefPubMedPubMedCentral

Liu J, Wu J, Zhou L et al (2015) ZD6474, a new treatment strategy for human osteosarcoma, and its potential synergistic effect with celecoxib. Oncotarget 6(25):21341–21352. https://doi.org/10.18632/oncotarget.4179CrossRefPubMedPubMedCentral

MacEwen EG, Pastor J, Kutzke J et al (2004) IGF-1 receptor contributes to the malignant phenotype in human and canine osteosarcoma. J Cell Biochem 92(1):77–91. https://doi.org/10.1002/jcb.20046CrossRefPubMed

Machiels JPH, Haddad RI, Fayette J et al (2015) Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. Lancet Oncol 16(5):583–594. https://doi.org/10.1016/S1470-2045(15)70124-5CrossRefPubMed

Mirabello L, Troisi RJ, Savage SA (2009) Osteosarcoma incidence and survival rates from 1973 to 2004: data from the surveillance, epidemiology, and end results program. Cancer 115(7):1531–1543. https://doi.org/10.1002/cncr.24121CrossRefPubMedPubMedCentral

Normanno N, De Luca A, Bianco C et al (2006) Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366(1):2–16. https://doi.org/10.1016/j.gene.2005.10.018CrossRef

Ottaviani G, Jaffe N (2009) The epidemiology of osteosarcoma. Cancer Treat Res 152:3–13. https://doi.org/10.1007/978-1-4419-0284-9_1CrossRefPubMed

Scotlandi K, Manara MC, Hattinger CM et al (2005) Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing’s sarcoma. Eur J Cancer 41(9):1349–1361. https://doi.org/10.1016/j.ejca.2005.03.015CrossRefPubMed

Sevelda F, Mayr L, Kubista B et al (2015) EGFR is not a major driver for osteosarcoma cell growth in vitro but contributes to starvation and chemotherapy resistance. J Exp Clin Cancer Res 34(1):134. https://doi.org/10.1186/s13046-015-0251-5CrossRefPubMedPubMedCentral

Solca F, Dahl G, Zoephel A et al (2012) Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 343(2):342–350. https://doi.org/10.1124/jpet.112.197756CrossRef

Soria JC, Felip E, Cobo M et al (2015) Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet Oncol 16(8):897–907. https://doi.org/10.1016/S1470-2045(15)00006-6CrossRefPubMed

Wen YH, Koeppen H, Garcia R et al (2007) Epidermal growth factor receptor in osteosarcoma: expression and mutational analysis. Hum Pathol 38(8):1184–1191. https://doi.org/10.1016/j.humpath.2007.01.002CrossRefPubMed

Wu PK, Chen WM, Chen CF et al (2009) Primary osteogenic sarcoma with pulmonary metastasis: clinical results and prognostic factors in 91 patients. Jpn J Clin Oncol 39(8):514–522. https://doi.org/10.1093/jjco/hyp057CrossRefPubMed

Yang JCH, Wu YL, Schuler M et al (2015) Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 16(2):141–151. https://doi.org/10.1016/S1470-2045(14)71173-8CrossRefPubMed

Young NR, Soneru C, Liu J et al (2015) Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo. Target Oncol 10(4):501–508. https://doi.org/10.1007/s11523-014-0353-6CrossRefPubMedPubMedCentral

Title: Afatinib is active in osteosarcoma in osteosarcoma cell lines
Authors: Marlid Cruz-Ramos
Yessica Zamudio-Cuevas
Daniel Medina-Luna
Karina Martínez-Flores
Gabriela Martínez-Nava
Javier Fernández-Torres
Alberto López-Reyes
Flavio Solca
Publication date: 01-07-2020
Publisher: Springer Berlin Heidelberg
Keywords: osteosarcoma
Osteosarcoma
Afatinib
Published in: Journal of Cancer Research and Clinical Oncology / Issue 7/2020
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-020-03220-y

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

ACC 2024 Congress

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2020

Molecular characterization of prostate cancer in Middle Eastern population highlights differences with Western populations with prognostic implication

Impact of successful local ablative bridging therapy prior to liver transplantation on long-term survival in patients with hepatocellular carcinoma in cirrhosis

Use of GoFundMe® to crowdfund complementary and alternative medicine treatments for cancer

A quick evaluation method of nosocomial infection risk for cancer hospitals during the COVID-19 pandemic

Molecular pathways in vulvar squamous cell carcinoma: implications for target therapeutic strategies